Compare Stocks: RXRX, CRSP, MIRM, and CGON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.35	$73.79	$32.57 ▼ $80.97	$6.41B	0.24	639,213 shs	759,833 shs
CRSP CRISPR Therapeutics	$51.72	$53.49	$44.12 ▼ $78.48	$5.00B	1.76	1.42 million shs	855,572 shs
MIRM Mirum Pharmaceuticals	$98.22	$106.81	$63.23 ▼ $130.00	$6.38B	0.49	455,605 shs	441,099 shs
RXRX Recursion Pharmaceuticals	$3.20	$3.29	$2.77 ▼ $7.18	$1.71B	1.07	15.12 million shs	8.01 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-3.11%	-3.57%	+21.49%	+117.01%
CRSP CRISPR Therapeutics	0.00%	-7.30%	-3.42%	-1.69%	-8.07%
MIRM Mirum Pharmaceuticals	0.00%	-2.66%	-2.40%	-2.75%	+32.18%
RXRX Recursion Pharmaceuticals	0.00%	-11.85%	+1.27%	-2.74%	-33.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.35	$73.79	$32.57 ▼ $80.97	$6.41B	0.24	639,213 shs	759,833 shs
CRSP CRISPR Therapeutics	$51.72	$53.49	$44.12 ▼ $78.48	$5.00B	1.76	1.42 million shs	855,572 shs
MIRM Mirum Pharmaceuticals	$98.22	$106.81	$63.23 ▼ $130.00	$6.38B	0.49	455,605 shs	441,099 shs
RXRX Recursion Pharmaceuticals	$3.20	$3.29	$2.77 ▼ $7.18	$1.71B	1.07	15.12 million shs	8.01 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-3.11%	-3.57%	+21.49%	+117.01%
CRSP CRISPR Therapeutics	0.00%	-7.30%	-3.42%	-1.69%	-8.07%
MIRM Mirum Pharmaceuticals	0.00%	-2.66%	-2.40%	-2.75%	+32.18%
RXRX Recursion Pharmaceuticals	0.00%	-11.85%	+1.27%	-2.74%	-33.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	21.32% Upside
CRSP CRISPR Therapeutics	2.61	Moderate Buy	$68.06	31.58% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.31	39.80% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	151.88% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, MIRM, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/31/2026	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$82.00
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/27/2026	MIRM Mirum Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$137.00
8/25/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,587.40	N/A	N/A	$9.33 per share	7.75
CRSP CRISPR Therapeutics	$3.51M	1,424.73	N/A	N/A	$20.17 per share	2.56
MIRM Mirum Pharmaceuticals	$521.31M	12.23	$0.05 per share	1,926.67	$6.12 per share	16.05
RXRX Recursion Pharmaceuticals	$74.68M	22.94	N/A	N/A	$2.14 per share	1.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)

Latest RXRX, CRSP, MIRM, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
CRSP CRISPR Therapeutics	0.34	17.85	17.85
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
CRSP CRISPR Therapeutics	69.20%
MIRM Mirum Pharmaceuticals	N/A
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
CRSP CRISPR Therapeutics	5.20%
MIRM Mirum Pharmaceuticals	8.32%
RXRX Recursion Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
RXRX Recursion Pharmaceuticals	600	535.34 million	499.74 million	Optionable

RXRX, CRSP, MIRM, and CGON Headlines

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells 22,408 Shares

September 10, 2026 | marketbeat.com

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

September 10, 2026 | zacks.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.9% Higher - Here's What Happened

September 4, 2026 | marketbeat.com

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

September 4, 2026 | zacks.com

Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?

September 3, 2026 | zacks.com

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 30,000 Shares

September 3, 2026 | insidertrades.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock

September 2, 2026 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Sell at Wall Street Zen

August 29, 2026 | marketbeat.com

Recursion Pharmaceuticals, Inc. (RXRX)

August 26, 2026 | finance.yahoo.com

Stock Traders Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

August 26, 2026 | marketbeat.com

Bank of America Corp DE Buys 384,486 Shares of Recursion Pharmaceuticals, Inc. $RXRX

August 26, 2026 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.3% - Here's What Happened

August 25, 2026 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 7% - Here's What Happened

August 24, 2026 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Rating of "Hold" by Analysts

August 24, 2026 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.8% - Still a Buy?

August 19, 2026 | marketbeat.com

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

August 18, 2026 | finance.yahoo.com

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

August 17, 2026 | finance.yahoo.com

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

August 17, 2026 | zacks.com

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates

August 17, 2026 | marketbeat.com

Recursion (RXRX) Q2 2026 Earnings Call Transcript

August 12, 2026 | fool.com

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, MIRM, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

$72.35 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$72.31 -0.04 (-0.06%)

As of 09/11/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

CRISPR Therapeutics NASDAQ:CRSP

$51.72 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$51.76 +0.05 (+0.09%)

As of 09/11/2026 07:47 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Mirum Pharmaceuticals NASDAQ:MIRM

$98.22 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$98.27 +0.05 (+0.05%)

As of 09/11/2026 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.20 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.20 -0.01 (-0.16%)

As of 09/11/2026 07:58 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, MIRM, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CRSP, MIRM, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CRSP, MIRM, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, MIRM, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

CRISPR Therapeutics NASDAQ:CRSP

Mirum Pharmaceuticals NASDAQ:MIRM

Recursion Pharmaceuticals NASDAQ:RXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, MIRM, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CRSP, MIRM, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CRSP, MIRM, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, MIRM, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

CRISPR Therapeutics NASDAQ:CRSP

Mirum Pharmaceuticals NASDAQ:MIRM

Recursion Pharmaceuticals NASDAQ:RXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools